Adaptive auto-regulation of androgen receptor provides a paradigm shifting rationale for bipolar androgen therapy (BAT) for castrate resistant human prostate cancer.
about
Challenges to treat hypogonadism in prostate cancer patients: implications for endocrinologists, urologists and radiotherapistsCancer/Testis Antigens: "Smart" Biomarkers for Diagnosis and Prognosis of Prostate and Other CancersSupraphysiological androgen levels induce cellular senescence in human prostate cancer cells through the Src-Akt pathway.Androgen receptor as a targeted therapy for breast cancer.Androgen receptor (AR) suppresses normal human prostate epithelial cell proliferation via AR/β-catenin/TCF-4 complex inhibition of c-MYC transcription.Androgen Deprivation Followed by Acute Androgen Stimulation Selectively Sensitizes AR-Positive Prostate Cancer Cells to Ionizing Radiation.Testosterone therapy and prostate cancer.The role of intracrine androgen metabolism, androgen receptor and apoptosis in the survival and recurrence of prostate cancer during androgen deprivation therapy.Testosterone Therapy in Men With Prostate Cancer.Phase I and II therapies targeting the androgen receptor for the treatment of castration resistant prostate cancer.Novel mechanism-based therapeutics for androgen axis blockade in castration-resistant prostate cancer.The Role of Testosterone in the Treatment of Castration-Resistant Prostate Cancer.Transient exposure to androgens induces a remarkable self-sustained quiescent state in dispersed prostate cancer cells.Analytic Validation of RNA In Situ Hybridization (RISH) for AR and AR-V7 Expression in Human Prostate Cancer.Phosphorylation-induced conformational dynamics in an intrinsically disordered protein and potential role in phenotypic heterogeneity.Testosterone Therapy Among Prostate Cancer Survivors.Effect of bipolar androgen therapy for asymptomatic men with castration-resistant prostate cancer: results from a pilot clinical study.Testosterone boosts for treatment of castration resistant prostate cancer: an experimental implementation of intermittent androgen deprivation.Of mice and men--warning: intact versus castrated adult male mice as xenograft hosts are equivalent to hypogonadal versus abiraterone treated aging human males, respectivelyHarnessing Solute Carrier Transporters for Precision Oncology.Treatment strategies for DNA repair-deficient prostate cancer.Phenotypic Plasticity and Cell Fate Decisions in Cancer: Insights from Dynamical Systems TheoryFrom bench to bedside: bipolar androgen therapy in a pilot clinical study.Negative regulation of the androgen receptor gene through a primate-specific androgen response element present in the 5' UTR.Exploiting AR-Regulated Drug Transport to Induce Sensitivity to the Survivin Inhibitor YM155.Deletion of tumor suppressors adenomatous polyposis coli and Smad4 in murine luminal epithelial cells causes invasive prostate cancer and loss of androgen receptor expression.Bipolar androgen therapy in men with metastatic castration-resistant prostate cancer after progression on enzalutamide: an open-label, phase 2, multicohort study.Supraphysiologic Testosterone Therapy in the Treatment of Prostate Cancer: Models, Mechanisms and Questions.Bipolar Androgen Therapy for Men With Androgen Ablation Naïve Prostate Cancer: Results From the Phase II BATMAN Study.[Antihormonal therapy in prostate cancer : Side effects].Episode-like pulse testosterone supplementation induces tumor senescence and growth arrest down-modulating androgen receptor through modulation of p-ERK1/2, pARser81 and CDK1 signaling: biological implications for men treated with testosterone replaRationale for bipolar androgen therapy (BAT) for metastatic prostate cancer.Phenotypic Plasticity, Bet-Hedging, and Androgen Independence in Prostate Cancer: Role of Non-Genetic Heterogeneity.Supraphysiological Testosterone Therapy as Treatment for Castration-Resistant Prostate Cancer.Bipolar Androgen Therapy: A Paradoxical Approach for the Treatment of Castration-resistant Prostate Cancer.Resolving the Coffey Paradox: what does the androgen receptor do in normal vs. malignant prostate epithelial cells?
P2860
Q26773738-74475DDF-F62B-4678-AD20-7761D24AEA21Q33624448-854181D0-E776-425C-AEBB-10D34803895DQ34227242-A36E04DD-F506-495C-898F-6496353FC934Q36135807-E1ABBA5C-B0CE-4486-A7CA-7DB481761087Q36867637-740B3629-E7C6-4570-907E-F07A5E09BF2BQ37059814-DCF78D32-A0E8-45DD-8852-6D3B39C9859DQ37531045-EFB0891C-6985-417E-A366-85817E445590Q37709925-1F0F691C-CF1D-46DE-B037-B2869302599CQ38683604-0203A54E-0849-4CEF-8F11-22FB589BA7AFQ38765489-5F9B0336-61EF-46EC-9209-AD7A42866F39Q38775459-392D70FF-BB66-443D-8ACC-E73B2B31D8B1Q38810776-CB47308D-B8EB-4E76-9CCD-041F8DDDF848Q38828800-8FB7B016-1BA5-4255-8B1A-39A296B2F5F2Q38868832-6449AEFE-969B-41CA-85F3-F98598B6C040Q38910392-2515D998-5C61-46CD-B5D7-9C47D65BD9ACQ38913362-48632209-C311-48BC-B592-0047ABEA87BAQ38922304-D6F070A4-860C-4920-931B-D3E1587AF16EQ39123647-091E93CD-4644-4465-8197-80E6AA133CB4Q39138350-AC0282B6-D5C0-4208-889A-C72A008359C9Q39204754-E2527C54-1847-45FA-915D-12B1AD8633DDQ39345771-0AC5C0E0-4FCF-4C91-8FB2-6A6EA648E5B6Q39390852-C4186125-3D1D-4FC1-82CC-69FBB942F787Q42120157-17092B75-F22B-4C2B-97A6-5A87AB0AD539Q42878519-5C5B7ED4-06FD-461B-943B-DB07AB6C3368Q45058251-3A865B8C-DFA1-4E1C-B164-DDD9FD6CE9FCQ47097550-76C1287B-C3A3-4FDD-89BD-6CB3EFF8B296Q47191382-668D47D3-261A-455B-9092-26628D2B2590Q47359141-F0E5FC41-9FC7-48D3-97F8-569875393052Q47716531-B3D286D8-A611-4BEF-A3F3-F604D881CDFEQ48744603-CC69D76E-B38E-49DE-9E45-7592B6C721A6Q49631417-07EECDA7-18EB-4895-BC53-740218ED8F84Q52758659-1B65661D-158B-4D24-80C0-B3BD11BA53D1Q53078069-34F4FF3C-EDF5-40ED-91A2-C4493DFF7EE5Q55096243-9D092C5A-6EC4-41D5-A0FF-057265B5281CQ55112139-41E31CD4-2785-4932-9EFF-61EED0F22C03Q55315541-F4DC26CD-2A26-43F6-BCA5-491280373290
P2860
Adaptive auto-regulation of androgen receptor provides a paradigm shifting rationale for bipolar androgen therapy (BAT) for castrate resistant human prostate cancer.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Adaptive auto-regulation of an ...... sistant human prostate cancer.
@en
Adaptive auto-regulation of an ...... e for bipolar androgen therapy
@nl
type
label
Adaptive auto-regulation of an ...... sistant human prostate cancer.
@en
Adaptive auto-regulation of an ...... e for bipolar androgen therapy
@nl
prefLabel
Adaptive auto-regulation of an ...... sistant human prostate cancer.
@en
Adaptive auto-regulation of an ...... e for bipolar androgen therapy
@nl
P2093
P2860
P356
P1433
P1476
Adaptive auto-regulation of an ...... sistant human prostate cancer.
@en
P2093
Georges H Ndikuyeze
Jason M D'Antonio
John T Isaacs
Lizamma Antony
Samuel R Denmeade
Shuangling Chen
Susan P Dalrymple
P2860
P304
P356
10.1002/PROS.22504
P577
2012-03-06T00:00:00Z